Claims for Patent: 10,654,827

Summary for Patent: 10,654,827

Title:	Therapeutic compounds
Abstract:	The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb):
Inventor(s):	Graupe Michael, Henry Steven J., Link John O., Saito Roland D., Schroeder Scott D., Stefanidis Dimitrios, Tse Winston C., Zhang Jennifer R.
Assignee:	Gilead Sciences, Inc.
Application Number:	US16016718
Patent Claims:	3. The method of claim 1 , wherein the method comprises administering the compound claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in combination with one claim 1 , two claim 1 , three claim 1 , or four additional therapeutic agents.4. The method of claim 3 , wherein the additional therapeutic agents are selected from the group consisting of combination drugs for HIV claim 3 , HIV protease inhibitors claim 3 , HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase claim 3 , HIV nucleoside or nucleotide inhibitors of reverse transcriptase claim 3 , HIV integrase inhibitors claim 3 , HIV non-catalytic site (or allosteric) integrase inhibitors claim 3 , HIV entry inhibitors claim 3 , HIV maturation inhibitors claim 3 , latency reversing agents claim 3 , compounds that target the HIV capsid claim 3 , immune-based therapies claim 3 , phosphatidylinositol 3-kinase (PI3K) inhibitors claim 3 , HIV antibodies claim 3 , bispecific antibodies claim 3 , HIV p17 matrix protein inhibitors claim 3 , IL-13 antagonists claim 3 , peptidyl-prolyl cis-trans isomerase A modulators claim 3 , protein disulfide isomerase inhibitors claim 3 , complement C5a receptor antagonists claim 3 , DNA methyltransferase inhibitor claim 3 , HIV vif gene modulators claim 3 , Vif dimerization antagonists claim 3 , HIV-1 viral infectivity factor inhibitors claim 3 , TAT protein inhibitors claim 3 , HIV-1 Nef modulators claim 3 , Hck tyrosine kinase modulators claim 3 , mixed lineage kinase-3 (MLK-3) inhibitors claim 3 , HIV-1 splicing inhibitors claim 3 , Rev protein inhibitors claim 3 , integrin antagonists claim 3 , nucleoprotein inhibitors claim 3 , splicing factor modulators claim 3 , COMM domain containing protein 1 modulators claim 3 , HIV ribonuclease H inhibitors claim 3 , retrocyclin modulators claim 3 , CDK-9 inhibitors claim 3 , dendritic ICAM-3 grabbing nonintegrin 1 inhibitors claim 3 , HIV GAG protein inhibitors claim 3 , HIV POL protein inhibitors claim 3 , Complement Factor H modulators claim 3 , ubiquitin ligase inhibitors claim 3 , deoxycytidine kinase inhibitors claim 3 , cyclin dependent kinase inhibitors claim 3 , proprotein convertase PC9 stimulators claim 3 , ATP dependent RNA helicase DDX3X inhibitors claim 3 , reverse transcriptase priming complex inhibitors claim 3 , G6PD and NADH-oxidase inhibitors claim 3 , pharmacokinetic enhancers claim 3 , HIV gene therapy claim 3 , and HIV vaccines claim 3 , or any combinations thereof.5. The method of claim 3 , wherein the additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds claim 3 , HIV non-nucleoside inhibitors of reverse transcriptase claim 3 , HIV non-nucleotide inhibitors of reverse transcriptase claim 3 , HIV nucleoside inhibitors of reverse transcriptase claim 3 , HIV nucleotide inhibitors of reverse transcriptase claim 3 , HIV integrase inhibitors claim 3 , gp41 inhibitors claim 3 , CXCR4 inhibitors claim 3 , gp120 inhibitors claim 3 , CCR5 inhibitors claim 3 , capsid polymerization inhibitors claim 3 , and pharmacokinetic enhancers claim 3 , or any combinations thereof.6. The method of claim 3 , wherein the additional therapeutic agents are selected from the group consisting of abacavir sulfate claim 3 , tenofovir claim 3 , tenofovir disoproxil claim 3 , tenofovir disoproxil fumarate claim 3 , tenofovir disoproxil hemifumarate claim 3 , tenofovir alafenamide claim 3 , and tenofovir alafenamide hemifumarate.7. The method of claim 3 , wherein the additional therapeutic agents are selected from the group consisting of tenofovir alafenamide claim 3 , tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate.8. The method of claim 3 , wherein the method comprises administering the compound claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , in combination with 4′-ethynyl-2-fluoro-2′-deoxyadenosine claim 3 , bictegravir claim 3 , or a pharmaceutically acceptable salt thereof.11. The method of claim 9 , wherein the method comprises administering the compound claim 9 , or a pharmaceutically acceptable salt thereof claim 9 , in combination with one claim 9 , two claim 9 , three claim 9 , or four additional therapeutic agents.12. The method of claim 11 , wherein the additional therapeutic agents are selected from the group consisting of combination drugs for HIV claim 11 , HIV protease inhibitors claim 11 , HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase claim 11 , HIV nucleoside or nucleotide inhibitors of reverse transcriptase claim 11 , HIV integrase inhibitors claim 11 , HIV non-catalytic site (or allosteric) integrase inhibitors claim 11 , HIV entry inhibitors claim 11 , HIV maturation inhibitors claim 11 , latency reversing agents claim 11 , compounds that target the HIV capsid claim 11 , immune-based therapies claim 11 , phosphatidylinositol 3-kinase (PI3K) inhibitors claim 11 , HIV antibodies claim 11 , bispecific antibodies claim 11 , HIV p17 matrix protein inhibitors claim 11 , IL-13 antagonists claim 11 , peptidyl-prolyl cis-trans isomerase A modulators claim 11 , protein disulfide isomerase inhibitors claim 11 , complement C5a receptor antagonists claim 11 , DNA methyltransferase inhibitor claim 11 , HIV vif gene modulators claim 11 , Vif dimerization antagonists claim 11 , HIV-1 viral infectivity factor inhibitors claim 11 , TAT protein inhibitors claim 11 , HIV-1 Nef modulators claim 11 , Hck tyrosine kinase modulators claim 11 , mixed lineage kinase-3 (MLK-3) inhibitors claim 11 , HIV-1 splicing inhibitors claim 11 , Rev protein inhibitors claim 11 , integrin antagonists claim 11 , nucleoprotein inhibitors claim 11 , splicing factor modulators claim 11 , COMM domain containing protein 1 modulators claim 11 , HIV ribonuclease H inhibitors claim 11 , retrocyclin modulators claim 11 , CDK-9 inhibitors claim 11 , dendritic ICAM-3 grabbing nonintegrin 1 inhibitors claim 11 , HIV GAG protein inhibitors claim 11 , HIV POL protein inhibitors claim 11 , Complement Factor H modulators claim 11 , ubiquitin ligase inhibitors claim 11 , deoxycytidine kinase inhibitors claim 11 , cyclin dependent kinase inhibitors claim 11 , proprotein convertase PC9 stimulators claim 11 , ATP dependent RNA helicase DDX3X inhibitors claim 11 , reverse transcriptase priming complex inhibitors claim 11 , G6PD and NADH-oxidase inhibitors claim 11 , pharmacokinetic enhancers claim 11 , HIV gene therapy claim 11 , and HIV vaccines claim 11 , or any combinations thereof.13. The method of claim 11 , wherein the additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds claim 11 , HIV non-nucleoside inhibitors of reverse transcriptase claim 11 , HIV non-nucleotide inhibitors of reverse transcriptase claim 11 , HIV nucleoside inhibitors of reverse transcriptase claim 11 , HIV nucleotide inhibitors of reverse transcriptase claim 11 , HIV integrase inhibitors claim 11 , gp41 inhibitors claim 11 , CXCR4 inhibitors claim 11 , gp120 inhibitors claim 11 , CCR5 inhibitors claim 11 , capsid polymerization inhibitors claim 11 , and pharmacokinetic enhancers claim 11 , or any combinations thereof.14. The method of claim 11 , wherein the additional therapeutic agents are selected from the group consisting of 4′-ethynyl-2-fluoro-2′-deoxyadenosine claim 11 , bictegravir or a pharmaceutically acceptable salt thereof claim 11 , abacavir sulfate claim 11 , tenofovir claim 11 , tenofovir disoproxil claim 11 , tenofovir disoproxil fumarate claim 11 , tenofovir disoproxil hemifumarate claim 11 , tenofovir alafenamide claim 11 , and tenofovir alafenamide hemifumarate.15. The method of claim 11 , wherein the additional therapeutic agents are selected from the group consisting of 4′-ethynyl-2-fluoro-2′-deoxyadenosine claim 11 , bictegravir or a pharmaceutically acceptable salt thereof claim 11 , tenofovir alafenamide claim 11 , tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate.